Amendment: SEC Form SC 13G/A filed by Enliven Therapeutics Inc.

$ELVN
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $ELVN alert in real time by email
SC 13G/A 1 tm2427061d10_sc13ga.htm SC 13G/A

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G*

(Rule 13d-102)

 

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO § 240.13d-2

(Amendment No. 2)*

 

 

Enliven Therapeutics, Inc.
(Name of Issuer)
 
Common Stock, $0.001 par value per share (the “Shares”)
(Title of Class of Securities)
 
29337E102
(CUSIP Number)
 
September 30, 2024
(Date of Event Which Requires Filing of the Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)
x Rule 13d-1(c)
o Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 29337E102 13G Page 2 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Advisors LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

1,733,977 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.7%1

12.

TYPE OF REPORTING PERSON

 

IA; OO; HC

       

 

_________________________

1 The percentages reported in this Schedule 13G are based upon 47,237,207 Shares outstanding as of August 1, 2024 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on August 13, 2024).

 

 

 

 

CUSIP No. 29337E102 13G Page 3 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Advisors Holdings LP

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

1,733,977 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.7%

12.

TYPE OF REPORTING PERSON

 

PN; HC

       

 

 

 

 

CUSIP No. 29337E102 13G Page 4 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel GP LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

1,733,977 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.7%

12.

TYPE OF REPORTING PERSON

 

OO; HC

       

 

 

 

 

CUSIP No. 29337E102 13G Page 5 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

117 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.0%

12.

TYPE OF REPORTING PERSON

 

BD; OO

       

 

 

 

 

CUSIP No. 29337E102 13G Page 6 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities Group LP

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

117 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.0%

12.

TYPE OF REPORTING PERSON

 

PN; HC

       

 

 

 

 

CUSIP No. 29337E102 13G Page 7 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Citadel Securities GP LLC

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Delaware

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

117 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

0.0%

12.

TYPE OF REPORTING PERSON

 

OO; HC

       

 

 

 

 

CUSIP No. 29337E102 13G Page 8 of 13 Pages

 

 

1.

NAME OF REPORTING PERSONS

 

Kenneth Griffin

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     o

(b)     o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

U.S. Citizen

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5.

SOLE VOTING POWER

 

0

6.

SHARED VOTING POWER

 

1,734,094 Shares

7.

SOLE DISPOSITIVE POWER

 

0

8.

SHARED DISPOSITIVE POWER

 

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

See Row 6 above

10.

CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

o

 

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

3.7%

12.

TYPE OF REPORTING PERSON

 

IN; HC

       

 

 

 

 

CUSIP No. 29337E102 13G Page 9 of 13 Pages

 

 

Item 1(a). Name of Issuer:
   
  Enliven Therapeutics, Inc.
   
Item 1(b). Address of Issuer’s Principal Executive Offices:
   
  6200 Lookout Road, Boulder, CO 80301 
   
Item 2(a). Name of Person Filing:
   
  This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), Citadel CEMF Investments Ltd., a Cayman Islands limited company (“CCIL”), and Citadel Securities. Such owned Shares may include other instruments exercisable for or convertible into Shares.
   
  Citadel Advisors is the portfolio manager for CM and CCIL.  CAH is the sole member of Citadel Advisors.  CGP is the general partner of CAH.  CALC4 is the non-member manager of Citadel Securities.  CSGP is the general partner of CALC4.  Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
   
  The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
   
Item 2(b). Address or Principal Business Office or, if none, Residence:
   
  The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
   
Item 2(c). Citizenship:
   
  Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware.  Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware.  Mr. Griffin is a U.S. citizen.
   
Item 2(d). Title of Class of Securities:
   
  Common Stock, $0.001 par value per share
   
Item 2(e). CUSIP Number:
   
  29337E102

 

 

 

 

CUSIP No. 29337E102 13G Page 10 of 13 Pages

 

 

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
   
  (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
  (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
  (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
  (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
  (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
  (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
  (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
  (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
  (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
  (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
  (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
         
  If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
         
Item 4. Ownership:
         
  A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
         
    (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 1,733,977 Shares.
         
    (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 3.7% of the Shares outstanding.
         
    (c) Number of Shares as to which such person has:
         
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  1,733,977
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  1,733,977

 

 

 

 

CUSIP No. 29337E102 13G Page 11 of 13 Pages

 

 

  B. Citadel Securities LLC
         
    (a) Citadel Securities LLC may be deemed to beneficially own 117 Shares.
       
    (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
       
    (c) Number of shares of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  117
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  117
         
  C. Citadel Securities Group LP and Citadel Securities GP LLC
         
    (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 117 Shares.
       
    (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
       
    (c) Number of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  117
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  117
         

 

 

 

 

CUSIP No. 29337E102 13G Page 12 of 13 Pages

 

 

  D. Kenneth Griffin
         
    (a) Mr. Griffin may be deemed to beneficially own 1,734,094 Shares.
       
    (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 3.7% of the Shares outstanding.
       
    (c) Number of Shares as to which such person has:
       
      (i) sole power to vote or to direct the vote:  0
         
      (ii) shared power to vote or to direct the vote:  1,734,094
         
      (iii) sole power to dispose or to direct the disposition of:  0
         
      (iv) shared power to dispose or to direct the disposition of:  1,734,094

 

Item 5. Ownership of Five Percent or Less of a Class:
   
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. x
   
Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
   
  Not Applicable
   
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
   
  Not Applicable
   
Item 8. Identification and Classification of Members of the Group:
   
  Not Applicable
   
Item 9. Notice of Dissolution of Group:
   
  Not Applicable
   
Item 10. Certifications:
   
  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 

 

 

CUSIP No. 29337E102 13G Page 13 of 13 Pages

 

 

SIGNATURE

 

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

 

Dated November 14, 2024.

 

CITADEL SECURITIES LLC   CITADEL ADVISORS LLC  
           
By: /s/ Guy Miller   By: /s/ Seth Levy  
  Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
           
           
CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP  
           
By: /s/ Guy Miller   By: /s/ Seth Levy  
  Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
           
           
CITADEL SECURITIES GP LLC   CITADEL GP LLC  
           
By: /s/ Guy Miller   By: /s/ Seth Levy  
  Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory  
           
           
      KENNETH GRIFFIN  
           
      By: /s/ Seth Levy  
        Seth Levy, attorney-in-fact*  

 

 

_________________________

* Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein.  The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

 

 

 

Get the next $ELVN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ELVN

DatePrice TargetRatingAnalyst
12/13/2024$42.00Buy
BTIG Research
9/9/2024$37.00Buy
H.C. Wainwright
6/11/2024$32.00Outperform
Robert W. Baird
4/9/2024$34.00Buy
Mizuho
3/29/2023$27.00Buy
Jefferies
3/3/2023Outperform
TD Cowen
More analyst ratings

$ELVN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting

    BOULDER, Colo., April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Poster Presentation Details  Abstract 4712 – ELVN-002, a potent, selective HER2 inhibitor with a differentiated binding mode conferring the potential for enhanced efficacy in combination with HER2-targeting antibody-drug conjugates Date/Time: Tuesday, April 29, 2025, 9:00 a.m. – 12:

    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

    Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo., Mar. 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update, inclu

    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

    BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m. ET. The fireside chat will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventherapeutics.com/. The webcast will be archived for a period of 90 days following the conclusion of the live event. About Enliven TherapeuticsEnliven is a clin

    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ELVN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ELVN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$ELVN
SEC Filings

See more

$ELVN
Leadership Updates

Live Leadership Updates

See more
  • Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors

    BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e

    $ELVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

$ELVN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more